Seelos Therapeutics, Inc. has responded to a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, initially filed on February 2, 2024. The SEC's comment, dated February 8, 2024, pointed out that Seelos had not filed an annual report for the most recently completed fiscal year, which appeared to make the company ineligible to incorporate information by reference on Form S-1. In a letter addressed to the SEC dated February 16, 2024, Seelos acknowledged the requirement and advised that it intends to file its Annual Report on Form 10-K for the year ended December 31, 2023. Following this, the company plans to promptly file an amendment to the Registration Statement to incorporate the annual report by reference. The correspondence was signed by Raj Mehra, Ph.D., President and Chief Executive Officer of Seelos Therapeutics.

Seelos Therapeutics, Inc. has responded to a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, initially filed on February 2, 2024. The SEC's comment, dated February 8, 2024, pointed out that Seelos had not filed an annual report for the most recently completed fiscal year, which appeared to make the company ineligible to incorporate information by reference on Form S-1. In a letter addressed to the SEC dated February 16, 2024, Seelos acknowledged the requirement and advised that it intends to file its Annual Report on Form 10-K for the year ended December 31, 2023. Following this, the company plans to promptly file an amendment to the Registration Statement to incorporate the annual report by reference. The correspondence was signed by Raj Mehra, Ph.D., President and Chief Executive Officer of Seelos Therapeutics.